ImmunityBio short interest was 33.94% of the float on June 30th, according to new data we received from Benzinga. Short interest totaled 131,830,884 shares, which was a decrease of -2.46% from June 15th.
It is estimated that it would take 8.66 days for short sellers to buy back their shares, with current trading volumes.
ImmunityBio Hedge Fund Activity
We have seen 241 institutional investors add shares of ImmunityBio stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC removed 13,519,992 shares (-95.0%) from their portfolio in Q1 2026, for an estimated $103,698,338
- HRT FINANCIAL LP added 3,925,446 shares (+inf%) to their portfolio in Q1 2026, for an estimated $30,108,170
- ALPHACORE CAPITAL LLC removed 2,986,489 shares (-99.5%) from their portfolio in Q1 2026, for an estimated $22,906,370
- VOLORIDGE INVESTMENT MANAGEMENT, LLC added 2,927,552 shares (+inf%) to their portfolio in Q1 2026, for an estimated $22,454,323
- GOLDMAN SACHS GROUP INC removed 2,915,606 shares (-47.4%) from their portfolio in Q1 2026, for an estimated $22,362,698
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 2,475,223 shares (-67.7%) from their portfolio in Q1 2026, for an estimated $18,984,960
- SQUAREPOINT OPS LLC removed 1,494,713 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $11,464,448
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ImmunityBio Insider Trading Activity
ImmunityBio insiders have traded $IBRX stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $IBRX stock by insiders over the last 6 months:
- BARRY J. SIMON has made 0 purchases and 7 sales selling 450,000 shares for an estimated $4,140,898.
- CHRISTOBEL SELECKY has made 0 purchases and 6 sales selling 356,200 shares for an estimated $2,997,931.
- CHERYL COHEN sold 131,210 shares for an estimated $1,246,941
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ImmunityBio Analyst Ratings
Wall Street analysts have issued reports on $IBRX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 05/21/2026
- HC Wainwright & Co. issued a "Buy" rating on 02/23/2026
- Piper Sandler issued a "Overweight" rating on 01/20/2026
- D. Boral Capital issued a "Buy" rating on 01/20/2026
To track analyst ratings and price targets for ImmunityBio, check out Quiver Quantitative's $IBRX forecast page.
ImmunityBio Price Targets
Multiple analysts have issued price targets for $IBRX recently. We have seen 6 analysts offer price targets for $IBRX in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $15.0 on 06/02/2026
- Jeet Mukherjee from BTIG set a target price of $12.0 on 05/21/2026
- Jason Kolbert from D. Boral Capital set a target price of $23.0 on 05/05/2026
- Edward Tenthoff from Piper Sandler set a target price of $12.0 on 03/04/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
